Simcere Pharmaceutical Group Limited Share Price
Stocks
2096
HK0000658531
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
01:38:15 17/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 10.50 HKD | -0.47% |
|
-6.25% | -12.28% |
| 16/11 | Simcere Pharma Gets China Nod for Atopic Dermatitis Drug Trial | MT |
| 16/11 | Simcere Pharma's Sanbexin Sublingual Tablets Added to China Reimbursement List | MT |
| Market Cap | 343.68Cr 2.7TCr 311.99Cr 288.21Cr 260.01Cr 490.85Cr 32TCr 509.64Cr 3.47TCr 1.37TCr 17TCr 1.29TCr 1.26TCr 55TCr | P/E 2026 * |
13.2x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 323.79Cr 2.54TCr 293.94Cr 271.53Cr 244.96Cr 462.45Cr 30TCr 480.15Cr 3.27TCr 1.29TCr 16TCr 1.21TCr 1.19TCr 52TCr | EV / Sales 2026 * |
2.13x | EV / Sales 2027 * | 1.87x |
| Free-Float |
33.7% | Yield 2026 * |
4.04% | Yield 2027 * | 4.59% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2096 | Delayed | |
| SMHGF | Delayed | ||
| S2P | Real-time | ||
| S2P | Delayed | ||
| S2P | Delayed | ||
| S2P | Real-time |
| 1 day | -0.47% | ||
| 1 week | -6.25% | ||
| Current month | +3.55% | ||
| 1 month | -4.72% | ||
| 3 months | -13.51% | ||
| 6 months | -7.73% | ||
| Current year | -12.28% |
| 1 week | 10.33 | 11.15 | |
| 1 month | 9.86 | 11.38 | |
| Current year | 9.07 | 14.28 | |
| 1 year | 9.07 | 14.34 | |
| 3 years | 4.94 | 15.08 | |
| 5 years | 4.94 | 15.08 | |
| 10 years | 4.94 | 15.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CEO | Chief Executive Officer | 63 | 20/08/2026 |
Yunshu Zhou
CEO | Chief Executive Officer | 54 | 25/03/2026 |
Yushan Wan
DFI | Director of Finance/CFO | 55 | 19/11/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CHM | Chairman | 63 | 08/10/2012 |
Yushan Wan
BRD | Director/Board Member | 55 | 19/11/2019 |
Renhong Tang
BRD | Director/Board Member | 46 | 01/11/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/10/26 | Other | Chief Executive Officer | 2,00,000 | 0.0078% | ||
| 28/10/26 | Other | Director | 2,00,000 | 0.0078% | ||
| 20/08/26 | Other | Chairperson | -30,00,000 | 0.1168% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.47% | -6.25% | -24.19% | +45.83% | 345.35Cr | ||
| -1.13% | +0.25% | +38.06% | +140.43% | 1,27500Cr | ||
| -1.36% | -1.21% | +42.24% | +85.68% | 68TCr | ||
| -0.59% | -0.16% | +26.02% | +111.76% | 52TCr | ||
| -0.76% | +1.27% | +41.98% | +71.50% | 39TCr | ||
| -0.75% | -3.62% | +54.29% | +40.57% | 36TCr | ||
| -1.83% | -0.13% | +27.64% | +60.13% | 31TCr | ||
| -1.65% | -1.88% | +2.00% | +35.77% | 29TCr | ||
| -0.95% | -1.57% | +35.99% | +70.23% | 25TCr | ||
| +1.60% | +0.56% | +36.19% | +128.48% | 21TCr | ||
| Average | -0.94% | -0.12% | +28.02% | +79.04% | 43TCr | |
| Weighted average by Cap. | -1.44% | +0.76% | +35.54% | +96.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 152.36Cr 1.2TCr 138.32Cr 127.77Cr 115.27Cr 217.61Cr 14TCr 225.94Cr 1.54TCr 608.96Cr 7.68TCr 571.66Cr 559.62Cr 24TCr | 176.04Cr 1.38TCr 159.81Cr 147.62Cr 133.18Cr 251.42Cr 16TCr 261.05Cr 1.78TCr 703.57Cr 8.88TCr 660.48Cr 646.57Cr 28TCr |
| Net income | 26Cr 201.81Cr 23Cr 22Cr 19Cr 37Cr 2.4TCr 38Cr 259.9Cr 102.8Cr 1.3TCr 96Cr 94Cr 4.1TCr | 30Cr 238.58Cr 28Cr 25Cr 23Cr 43Cr 2.84TCr 45Cr 307.25Cr 121.53Cr 1.53TCr 114.08Cr 111.68Cr 4.84TCr |
| Net Debt | -20Cr -156.06Cr -18Cr -17Cr -15Cr -28Cr -1.86TCr -29Cr -200.98Cr -79Cr -1TCr -75Cr -73Cr -3.17TCr | -14Cr -110.53Cr -13Cr -12Cr -11Cr -20Cr -1.32TCr -21Cr -142.34Cr -56Cr -710.2Cr -53Cr -52Cr -2.24TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/26/17 | HK$10.50 | -0.47% | 38,83,000 |
| 16/26/16 | HK$10.55 | -0.28% | 30,77,000 |
| 13/26/13 | HK$10.58 | -2.85% | 23,65,537 |
| 12/26/12 | HK$10.89 | -0.18% | 25,00,600 |
| 11/26/11 | HK$10.91 | -1.09% | 32,01,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2096 Stock
Select your edition
All financial news and data tailored to specific country editions
















